BAYRY Stock Recent News
BAYRY LATEST HEADLINES
MYERSTOWN, Pa.--(BUSINESS WIRE)--Today, Bayer proudly celebrated the grand opening of its new 70,000 square foot expansion at its Myerstown facility, following a $44 million investment in 2022. This state-of-the-art facility is a testament to Bayer's commitment to providing trusted self-care solutions to consumers across North America while advancing meaningful engagement with the local community. The ribbon-cutting ceremony was attended by Bayer leaders, employees, elected officials, and membe.
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer to Unveil Latest NUBEQA® (darolutamide) Data and Prostate Cancer Research at American Urological Association (AUA) 2025 Annual Meeting.
The German company cites mounting costs from lawsuits blaming Roundup for causing cancer.
The FDA converts its accelerated approval to full approval for BAYRY's oncology drug, Vitrakvi, on positive data from confirmatory studies.
Here is how Bayer Aktiengesellschaft (BAYRY) and Lonza Group Ag (LZAGY) have performed compared to their sector so far this year.
Bayer said on Friday it was again petitioning the U.S. Supreme Court to sharply limit legal claims that its Roundup weedkiller causes cancer, seeking to avoid potentially billions of dollars in damages.
LEVERKUSEN, Germany--(BUSINESS WIRE)--Today Bayer – through its indirect subsidiary Monsanto – filed its petition for a writ of certiorari with the U.S. Supreme Court in the Durnell case, just three business days after the Missouri Supreme Court's decision created a pathway toward the high court's review. The company argues that a split among federal circuit courts in the Roundup™ personal injury litigation, on the cross-cutting question of whether federal law preempts state-based failure-to-wa.
BAYRY subsidiary Vividion Therapeutics doses the first patient in a phase I study on VVD-159642 to treat advanced solid tumors.
FMC signed a partnership agreement to bring Isoflex Active technology to European markets.
Bayer said on Tuesday it was preparing market launches this year of two new drugs that could each have annual peak sales of at least $1 billion, as it seeks to strengthen its pharmaceuticals business amid a high debt burden.